Journals / Turkish Journal of Endocrinology and Metabolism / 2017 / Cilt: 21 - Sayı: 1

Asemptomatik Primer Hiperparatiroidizmi Olan Hastalarda Nöropsiklojik Değişiklikler ve Yaşam Kalitesi

Neuropsychological Changes and Health-related Quality of Life in Patients with Asymptomatic Primary Hyperparathyroidism

Pages
9–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results suggest that HRQOL and neuropsychological changes should also be considered during the clinical follow-up of patients with APHT

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Data about neuropsychological impairment and health-related quality of life (HRQOL) in patients with asymptomatic primary hyperparathyroidism (APHPT) is limited.
📊
Key Findings & Data:Material and Method: Thirty-seven patients with APHPT and 37 controls were included.
💡
Conclusion & Impact:Our results suggest that HRQOL and neuropsychological changes should also be considered during the clinical follow-up of patients with APHT
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Data about neuropsychological impairment and health-related quality of life (HRQOL) in patients with asymptomatic primary hyperparathyroidism (APHPT) is limited. We aimed to investigate the HRQOL, neuropyschological impairment, including depression, anxiety in patients with APHPT who have mildly elevated serum calcium (Ca) levels. Material and Method: Thirty-seven patients with APHPT and 37 controls were included. The Beck Depression Inventory (BDI), Spielberger StateTrait Anxiety Inventory (STAI), and the General Health Questionnaire were administered in all patients, HRQOL was investigated using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).Results: Serum levels of Ca and parathyroid hormone (PTH) were significantly higher in patients than in controls [(10.92±0.66 vs. 9.49±0.66, p=0.016, and 133 vs. 52.95 (25-75.50), p<0.001), respectively]. The levels of serum vitamin D were lower in patients than in controls [12.85 (4.0-62.50) vs. 20.30 (5.90-55.00), p=0.041)]. The patient group had higher BDI scores than controls (12.49±10.34 vs. 7.46±5.33, p=0.011). Patients with APHPT showed lower scores in SF-36 mental health (60.55±20.75 vs. 69.62±14.31, p=0.034), SF-36 physical functioning (55.83±27.30 vs. 75.67±24.18, p=0.002), SF-36 social functioning (66.32±27.69 vs. 82.08±14.89, p=0.003), and SF-36 emotional role functioning (42.55±37.85 vs. 69.30±35.43, p=0.003). The patients showed higher STAI-1 scores (39.95±11.52 vs. 34.70±8.01, p=0.026). We observed that STAI-1 score positively correlated with serum Ca level (r=0.391; p=0.018); and PTH (r=0.341; p=0.042). Discussion: Our study demonstrated that patients with APHPT have more depressive and anxiety symptoms and lower HRQOL. Our results suggest that HRQOL and neuropsychological changes should also be considered during the clinical follow-up of patients with APHT

Özet

Amaç: Asemptomatik primer hiperparatiroidizmi (APHPT) olan hastalardaki yaşam kalitesi ve nöropsikolojik değişiklikler ile ilgili bilgilerimiz kısıtlıdır. Bu çalışmadaki amacımız serum kalsiyum (Ca) düzeyi orta derecede yüksek olan APHPT hastalarını yaşam kalitesi ve nöropsikolojik değşiklikler yönünden incelemektir. Gereç ve Yöntem: Çalışmaya APHPT tanısı olan 37 hasta ve 37 kişilik kontrol grubu dahil edilmiştir. Olguların depresyon, kaygı düzeylerini ve yaşam kalitelerini değerlendirmek amacıyla Beck Depresyon Envanteri (BDE), Genel Sağlık Anketi, Durumluk-Sürekli Kaygı Envanteri (STAI), Kısa Form (SF-36) ölçekleri kullanılmıştır. Bulgular: Serum Ca ve paratiroid hormon (PTH) düzeyleri hasta grubunda anlamlı olarak daha yüksekti (10,92±0,66 karşılık 9,49±0,66; p=0,016; ve 133 (34-736) karşılık 52,95 (25-75,50), p<0,001). Serum vitamin D düzeyleri hasta grubunda daha düşüktü [12,85 (4,0-62,50) karşılık 20,30 (5,90-55,00), p=0,041]. BDE puanı hasta grubunda anlamlı olarak daha yüksekti (12,49±10,34 karşılık 7,46±5,33; p=0,011). SF-36 ölçeği ile değerlendirilen yaşam kalitesinin bazı bileşenlerinin puanlarının hasta grubunda istatistiksel anlamlı olarak daha düşüktü. Sırasıyla: SF-36 mental sağlık (60,55±20,75 karşılık 69,62±14,31; p=0,034), SF-36 fiziksel fonksiyon (55,83±27,30 karşılık 75,67±24,18; p=0,002), SF-36 sosyal fonksiyon (66,32±27,69 karşılık 82,08±14,89; p=0,003), SF-36 emosyonel rol kısıtlaması (42,55±37,85 karşılık 69,30±35,43; p=0,003). Durumluk kaygı envanteri (STAI-1) puanı hasta grubunda anlamlı olarak daha yüksekti (39,95±11,52 karşılık 34,70±8,01; p=0,026). STAI-1 puanı ile serum Ca düzeyi (r=0,391; p=0,018); ve serum PTH düzeyi (r=0,341; p=0,042) arasında pozitif korelasyon olduğu tespit edildi. Tartışma: Çalışmamız APHT hastalarında depresif ve kaygı semptomlarının olduğunu, yaşam kalitesinin de olumsuz etkilendiğini göstermiştir. Çalışmamızın sonuçları, APHT hasta grubunun yaşam kalitesi ve nöropsikolojik değişiklikler açılarından da takip edilmesi gerektiğini göstermektedir

🔖

Cite This Article

YILMAZ, B. A., TÖRÜNER, F. B., DEĞERTEKİN, C. K., İYİDİR, Ö. T., KAYA, B., ÇAKIR, N. (2017). Asemptomatik Primer Hiperparatiroidizmi Olan Hastalarda Nöropsiklojik Değişiklikler ve Yaşam Kalitesi. Turkish Journal of Endocrinology and Metabolism, Cilt: 21 - Sayı: 1, 9–14. https://ajindex.com/articles/370862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255
  2. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92:3114-3121
  3. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3561-3569
  4. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92:1687-1692
  5. Lundgren E, Ljunghall S, Akerstrom G, Hetta J, Mallmin H, Rastad J. Case-control study on symptoms and signs of “asymptomatic” primary hyperparathyroidism. Surgery. 1998;124:980-985
  6. Dotzenrath CM, Kaetsch AK, Pfingsten H, Cupisti K, Weyerbrock N, Vossough A, Verde PE, Ohmann C. Neuropsychiatric and cognitive changes after surgery for primary hyperparathyroidism. World J Surg. 2006;30:680-685
  7. Hasse C, Sitter H, Bachmann S, Zielke A, Koller M, Nies C, Lorenz W, Rothmund M. How asymptomatic is asymptomatic primary hyperparathyroidism? Exp Clin Endocrinol Diabetes. 2000;108:265-274
  8. Prager G, Kalaschek A, Kaczirek K, Passler C, Scheuba C, Sonneck G, Niederle B. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery. 2002;132:930-935
  9. Burney RE, Jones KR, Christy B, Thompson NW. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery. 1999;125:608-614
  10. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513-518
  11. Sheldon DG, Lee FT, Neil NJ, Ryan JA Jr. Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg. 2002;137:1022-1026
  12. Kahal H, Aye M, R